Pharmacologic interactions of multidrug therapy for dyslipidemia

Related Experiment Video

Updated: May 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Nidhi Mehta1, Emil M deGoma

  • 1Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, 9 Gates Building 3400 Spruce Street, Philadelphia, PA 19103, USA. nidhi.mehta@uphs.upenn.edu

Current Atherosclerosis Reports
|January 10, 2013
PubMed

Insights

Even with statin therapy, significant risk for atherothrombotic cardiovascular disease persists. Non-statin lipid-lowering drugs offer a promising approach to further reduce cardiovascular risk by lowering atherogenic lipoproteins.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Residual risk for atherothrombotic cardiovascular disease remains high despite optimal statin therapy.
  • Low-density lipoprotein (LDL) and other atherogenic lipoproteins are key contributors to cardiovascular risk.
  • A critical unmet need exists for effective therapies beyond statins.

Purpose of the Study:

  • To evaluate the role of non-statin lipid-lowering therapies in managing dyslipidemia.
  • To assess the efficacy and safety of novel agents for cardiovascular risk reduction.
  • To address the persistent residual risk in patients with cardiovascular disease.

Main Methods:

  • Review of recent landmark clinical trials on non-statin lipid-lowering therapies.
  • Analysis of data on the effectiveness in reducing atherogenic lipoproteins.
  • Evaluation of safety profiles and tolerability of these agents.

Main Results:

  • Non-statin therapies demonstrate significant reductions in LDL cholesterol and other atherogenic lipoproteins.
  • Landmark trials provide robust evidence for the efficacy of these agents.
  • Safety and tolerability data support their use in specific patient populations.

Conclusions:

  • Non-statin lipid-lowering therapies are valuable additions to the management of dyslipidemia.
  • These therapies effectively address residual cardiovascular risk when added to statin treatment.
  • Further research continues to refine the role of non-statin agents in cardiovascular prevention.

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...